1-({5-chloro-2-[(2-methylpropyl)oxy]phenyl}methyl)-5-methyl-1H-pyrazole-3-carbonyl chloride | 913574-01-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-({5-chloro-2-[(2-methylpropyl)oxy]phenyl}methyl)-5-methyl-1H-pyrazole-3-carbonyl chloride
• 英文别名: 1-[[5-chloro-2-(2-methylpropoxy)phenyl]methyl]-5-methylpyrazole-3-carbonyl chloride
• CAS: 913574-01-3
• 化学式: C₁₆H₁₈Cl₂N₂O₂
• 分子量: 341.237
• InChiKey: ZUGQKDWHZLUKOW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-({5-chloro-2-[(2-methylpropyl)oxy]phenyl}methyl)-5-methyl-1H-pyrazole-3-carbonyl chloride 在 四氧化锇 sodium periodate 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 77.5h， 生成 1-({5-chloro-2-[(2-methylpropyl)oxy]phenyl}methyl)-N-(5-formyl-2-pyridinyl)-5-methyl-1H-pyrazole-3-carboxamide
  参考文献：
  名称：

  WO2006/114313

  摘要：

  公开号：
• 作为产物：
  描述：

  1-({5-chloro-2-[(2-methylpropyl)oxy]phenyl}methyl)-5-methyl-1H-pyrazole-3-carboxylic acid 在 氯化亚砜 作用下， 反应 1.5h， 以100%的产率得到1-({5-chloro-2-[(2-methylpropyl)oxy]phenyl}methyl)-5-methyl-1H-pyrazole-3-carbonyl chloride
  参考文献：
  名称：

  WO2006/114313

  摘要：

  公开号：

文献信息

• PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS
  申请人：Conway Elizabeth Ann

  公开号：US20090239845A1

  公开（公告）日：2009-09-24

  Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein Z, R 1 , R 2a , R 2b , R 10 , R 11 and R x are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

  公式（I）的化合物或其药学上可接受的衍生物：其中Z、R1、R2a、R2b、R10、R11和Rx的定义如规范所述，制备这种化合物的过程，包含这种化合物的药物组合物以及这种化合物在医学上的用途。
• Discovery of brain penetrant, soluble, pyrazole amide EP1 receptor antagonists
  作者：Adrian Hall、Andy Billinton、Alan K. Bristow、Susan H. Brown、Anita Chowdhury、Leanne Cutler、Gerard M.P. Giblin、Paul Goldsmith、Thomas G. Hayhow、Ian R. Kilford、Alan Naylor、Barry Passingham、D. Anthony Rawlings

  DOI：10.1016/j.bmcl.2008.05.118

  日期：2008.7

  We describe the discovery of a series of pyrazole amide EP1 receptor antagonists with good aqueous solubility and CNS penetration. In order to achieve solubility we investigated the incorporation of a basic group in the region of the molecule previously occupied by a carboxylic acid, which was known to be a key element of the pharmacophore. This study led to the identification of compounds such as 4h, 4j and 10b which demonstrated brain-to-blood ratios of 0.8: 1-2.0: 1 in addition to good solubility and metabolic stability. (c) 2008 Elsevier Ltd. All rights reserved.
• Non-acidic pyrazole EP1 receptor antagonists with in vivo analgesic efficacy
  作者：Adrian Hall、Andy Billinton、Susan H. Brown、Nicholas M. Clayton、Anita Chowdhury、Gerard M.P. Giblin、Paul Goldsmith、Thomas G. Hayhow、David N. Hurst、Ian R. Kilford、Alan Naylor、Barry Passingham、Lisa Winyard

  DOI：10.1016/j.bmcl.2008.04.018

  日期：2008.6

  Replacement of the carboxylic acid group in a series of previously described methylene-linked pyrazole EP1 receptor antagonists led to the discovery of amide, reversed amide and carbamate derivatives. Two compounds, 10a and 10b, were identified as brain penetrant compounds and both demonstrated efficacy in the CFA model of inflammatory pain. (C) 2008 Elsevier Ltd. All rights reserved.
• [EN] PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS<br/>[FR] COMPOSES DE PYRAZOLE UTILISES COMME LIGANDS DES RECEPTEURS DE LA PROSTAGLANDINE
  申请人：GLAXO GROUP LTD

  公开号：WO2006114313A1

  公开（公告）日：2006-11-02

  [EN] Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein Z, R¹ ,R^2a, R^2b, R¹⁰, R¹¹ and R^x are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.
  [FR] L'invention concerne des composés de formule (I) ou un dérivé pharmaceutiquement acceptable de ces composés. Dans cette formule Z, R¹, R^2a, R^2b, R¹⁰, R¹¹ et R^x sont tels que définis dans la description. L'invention concerne également un procédé de préparation de ces composés, des compositions pharmaceutiques renfermant ces composés ainsi que l'utilisation desdits composés dans un médicament.